# Indication of HSCT in Patients With Refractory/Relapse AA After First-line Standard Immunosuppressive Therapy Aged More Than 40 Years

> **NCT06646497** · PHASE2 · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 52 (estimated)

## Conditions studied

- Aplastic Anemia

## Interventions

- **BIOLOGICAL:** Allogeneic hematopoietic stem cell transplantation Stem cell source only Bone Marrow

## Key facts

- **NCT ID:** NCT06646497
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-24
- **Primary completion:** 2030-01-24
- **Final completion:** 2030-01-24
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06646497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06646497, "Indication of HSCT in Patients With Refractory/Relapse AA After First-line Standard Immunosuppressive Therapy Aged More Than 40 Years". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06646497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*